This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Here's Why You Should Hold on to Cerner (CERN) Stock for Now
by Zacks Equity Research
Cerner (CERN) likely to gain from focus on big-data based healthcare services.
Here's Why You Should Hold on to Allscripts (MDRX) Stock Now
by Zacks Equity Research
Strong prospects in Sunrise EHR platform to aid Allscripts (MDRX). However, intense competition in the MedTech space is a headwind.
Implied Volatility Surging for Allscripts (MDRX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Allscripts (MDRX) stock based on the movements in the options market lately.
Allscripts' Sunrise Abstracting Selected by Wyckoff Heights
by Nabaparna Bhattacharya
Allscripts' (MDRX) Sunrise Abstracting Solution gets picked by Wyckoff Heights Medical Center. The platform complements Allscripts Sunrise electronic health record unit.
Cerner (CERN) Strong on EHR Prospects, Competition Intense
by Zacks Equity Research
Cerner's (CERN) strong EHR prospects and global outlook aid the company; margins continue to decline.
Allscripts' Payerpath & ePrescribe Receive EHNAC Accreditation
by Zacks Equity Research
Accreditation by EHNAC indicates Allscripts' (MDRX) sustainability in health data processing and transactions in terms of industry-established standards and HIPAA regulations.
Allscripts Sunrise Picked by UK's Maidstone and Tunbridge Wells
by Zacks Equity Research
Allscripts' (MDRX) Sunrise platform witnesses a suite of developments, fortifying the company's global foothold.
Allscripts Gains From Strong Results in Q2, Competition Rife
by Zacks Equity Research
Allscripts (MDRX) continues to gain from solid Q2 results and EHR developments; a competitive industry is a concern.
Allscripts (MDRX) Q2 Earnings In Line, Revenues Top Estimates
by Zacks Equity Research
Allscripts (MDRX) gains from solid segmental performance in Q2; a decline in bookings discourages.
AllScripts Healthcare (MDRX) Matches Q2 Earnings Estimates
by Zacks Equity Research
AllScripts (MDRX) delivered earnings and revenue surprises of 0.00% and 0.07%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Why Is Allscripts Healthcare (MDRX) Up 9.8% Since Its Last Earnings Report?
by Zacks Equity Research
Allscripts Healthcare (MDRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Allscripts' iPro Anesthesia to be Administered by SingHealth
by Zacks Equity Research
Allscripts (MDRX) goes global, joining hands with Singapore-based hospital to implement iPro Anesthesia.
Allscripts Acquires HealthGrid to Improve Patient Outcome
by Zacks Equity Research
Allscripts' (MDRX) HealthGrid buyout to drive FollowMyHealth platform.
Allscripts (MDRX) Q1 Earnings & Revenues Lag, Bookings Rise
by Zacks Equity Research
Allscripts (MDRX) witnesses strong segmental performances; a solid guidance encourages.
MedTech Takes to Big Data Analytics: 3 Stocks Catch Eye
by Nabaparna Bhattacharya
Here we take a look at the major factors that are driving the importance of big data in the MedTech space.
Why Is Allscripts (MDRX) Down 11.3% Since its Last Earnings Report?
by Zacks Equity Research
Allscripts (MDRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is the Tax Repeal Only Glitter and No Gold for MedTech?
by Nabaparna Bhattacharya
While the MedTech fraternity is hopeful about the latest MedTech tax repeal, we would like to draw your attention to the slump in share price and net margin figures following the tax's abolition in 2015.
Allscripts (MDRX) Launches Avenel to Revamp EHR Platform
by Zacks Equity Research
Allscripts' (MDRX) innovation team comes up with a user-friendly application, Avenel, to aid patients and clinicians through EHR.
Allscripts' (MDRX) Fundamentals Strong Amid Stiff Competition
by Zacks Equity Research
Allscripts' (MDRX) promising fourth-quarter results and international hold are encouraging. Integration risks and cutthroat competition are likely to mar prospects.
Allscripts (MDRX) Q4 Earnings Meet, Revenues Beat Estimates
by Zacks Equity Research
Solid year-over-year growth in Client Services revenues drove Allscripts in Q4.
Allscripts (MDRX) Q3 Earnings Meet, Revenues Beat Estimates
by Zacks Equity Research
Allscripts' (MDRX) solid guidance for 2017 and a bullish long-term outlook are key highlights of Q3. The expansion in margins is encouraging.
Allscripts Rides High on Product Launches Amid Rising Costs
by Zacks Equity Research
Management at Allscripts Healthcare (MDRX) is focused on various restructuring initiatives, research and development plans and launch of exclusive products.
Allscripts' Latest Initiative Eradicates Price Ambiguity
by Zacks Equity Research
Lately, Allscripts' (MDRX) management has been focusing on various restructuring initiatives, research and development plans and launch of exclusive products.
Allscripts' (MDRX) dbMotion Platform Selected by SWSPHN
by Zacks Equity Research
The latest development is a significant addition to Allscripts' (MDRX) dbMotion Solution platform customer base. The company is poised to benefit from opportunities in the Asia-Pacific market.
Allscripts (MDRX) Up 13.3% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Allscripts (MDRX) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.